The cell cycle is a term used to describe the orderly sequence of events which ensure the faithful duplication of all the cellular components in their correct sequence and the partitioning of these components into two daughter cells. Two classes of genes and their protein products are employed to accomplish this process: (1) genes whose products are obligatory for progress through the cell cycle, G1 to S-to G2 to M phases, and (2) genes whose proteins act as checkpoints which monitor the efficacy and completion of these obligatory events and stop the progression through the cell cycle if conditions are not satisfactory (Hartwell & Weinert, 1989; Murray, 1992 ). An example of an essential function is the synthesis or activation of a set of enzymes, in late GI and early S-phase, which are required to produce the nucleoside triphosphate precursors for DNA replication. Without such enzyme activities, DNA would not be duplicated and the cycle would abort. Similarly, enzymes that duplicate the DNA templates, the proteins that package DNA and those involved in chromosome condensation, spindle attachment and segregation are all essential to cell cycle progression. Checkpoint controls monitor and regulate these events, ensuring that initiation of each event is dependent upon completion of the earlier event (Hartwell & Weinert, 1989) . The cell cycle will progress through each stage unless it is stopped and restarted by a checkpoint control. Thus, most checkpoints are not obligatory for progress through the cell cycle, but if they should fail to function the cycle may progress in an abnormal fashion, which could result in mistakes or errors in duplication or unequal segregation of components. This may in turn lead to cell death or even the production of abnormal cells which continue to replicate and eventually form a tumour.
Some checkpoint controls act and stop progression of the cell cycle, by modifying a group of essential proteins called the cyclins. Cyclins bind to and activate the catalytic subunits of protein kinases, termed cyclin-dependent kinases (cdk), which in turn phosphorylate a set of targets that drive the cycle through GI to S-to G2 and M phases (Hartwell & Weinert, 1989; Herskowitz et al., 1991) . Other checkpoint functions modify phosphorylation of the cyclin-dependent kinase itself, which contributes to the regulation of the activity of the kinase complex (Murray, 1993; Walworth et al., 1993) . Events external to the cell, such as the availability of nutrients or growth factors, influence checkpoint pathways Correspondence: A.J. Levine. Received 15 October 1993. which regulate the level or ability of cyclins to activate these cyclin-dependent kinase activities in a cell. In some cases, the checkpoint control circuit is stimulated by a signal transduction pathway, which in itself may be composed of a cellsurface receptor, a GTP-binding protein-GTPase, protein kinase activities and transcription factors (Herskowitz et al., 1991) . This signal transduction pathway is sensitive to factors such as external nutrient levels, and communicates to a checkpoint control that alters the level or activity of the cyclins and their kinases (Figure 1) .
While a large number of experiments with yeast, Xenopus and mammalian cells have led to this outline of events in the cell cycle, other approaches have identified the same sets of genes and gene functions as playing a critical role in the origins of cancer in human beings. It is becoming clear that cancer arises in humans because of the accumulation of mutations in two major classes of genes: the proto-oncogenes and the tumour-suppressor genes (Brugge et al., 1991; Levine, 1992a) . While a wide variety of diverse mechanisms may lead to mutations which contribute to cancer, there are three general results of these mutations: the overexpression of a gene and its product, the alteration of a gene product and the inactivation of the encoded protein. Oncogenes result from activating mutations which either raise the level of a protein in a cell or alter its function by mutation in the structural gene. Tumour-suppressor genes are commonly inactivated, resulting in a loss of function mutation. For these reasons, oncogene mutations are usually dominant to the wild-type allele, while tumour-suppressor genes are most commonly recessive to the normal allele. Increased levels of oncogene products are achieved by gene amplifications or chromosomal translocations, which bring together an oncogene and a region of DNA encoding signals for high rates of transcription. For example, the N-myc gene is found in high copy numbers (amplification) in some neuroblastomas while the c-myc oncogene is found in a translocated chromosome fragment adjacent to the immunoglobulin locus in some B-cell tumours (Brugge et al., 1991) . Other oncogenes, such as ras, are found to have a mutation in the structural gene which alters as specific amino acid and changes the regulation of this protein. The result of such a mutation is the continuous signalling for cell growth via an activated signal transduction pathway.
Conversely, the loss of function observed with tumoursuppressor genes corresponds to an increased risk for cancer. Tumour-suppressor genes are responsible for the inherited predispositions to cancer in human populations (see Table I ) as seen with the p53 gene, the retinoblastoma susceptibility (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992) or the p53 gene (Donehower et al., 1992) , permit cell division to occur in the developing embryo (these are therefore non-essential functions of the cell cycle), but these mutations predispose the mice to a higher incidence of cancer [in the heterozygous state for Rb and the homozygous or heterozygous state for p53 (Lavigueur et al., 1989; Donehower et al., 1992) ]. Somatic mutations in tumoursuppressor genes also contribute to the origins of cancer in humans (Levine, 1992b) . Commonly, one allele of a tumoursuppressor gene sustains a mutation which inactivates the function of its protein and then the second allele is lost via deletion or gene conversion, resulting in a loss of heterozygosity (LOH) or a reduction to homozygosity at that locus in the cells of the tumour . Returning the wild-type allele to the cancer cell will result in a loss of tumorigenic potential of that cell starting to take their place in the events of the cell cycle (Figure 1 ). (Kuerbitz et al., 1992) , resulting in either a delay in progress through the cell cycle to permit repair processes (Kastan et al., 1991) or the initiation of programmed cell death or apoptosis (Lowe et al., 1993) . Commonly, this takes the form of a missense mutation plus a selection for a reduction to homozygosity and thus a complete loss of the wild-type alleles . This is the hallmark of a tumour-suppressor gene. Second, mice that contain mutations in both p53 alleles that eliminate p53 functional proteins are normal at birth, but 100% of these mice develop cancers in a 6-9 month period (Donehower et al., 1992) . These null mutations prove that the loss of p53 function results in a predisposition to cancer. There are, however, several observations which suggest that the nature of p53 mutations in cancers is more complex than a simple loss of function. First, 85.6% of the mutations at the p53 locus in human cancers are missense mutations, resulting in a faulty or altered protein in the cell . This contrasts with other tumour-suppressor genes (Rb, APC) which have much higher frequencies of chain termination codons, deletions, exon-skipping mutations or frameshift mutations. Only 8.1% of the p53 mutations are deletions or insertions (and one-fifth of these still produce proteins in reading frame), 5.5% are nonsense mutations or frameshift mutations and 0.8% of these mutations are neutral and produce no amino acid changes (these data are summarised from 1,447 mutations from cancers of 51 different cell and tissue types; Levine et al., 1993) . Furthermore, when this spectrum of mutations is analysed for the position of missense mutations in the p53 gene (with 393 codons), the great majority of mutations (92.1%) are localised between codons 120 and 290 (see Figure 2 ). The nature of the few mutations found outside of this region of the gene is instructive. For example, six independent mutations each have occurred at codon 298 and codon 342, and all 12 of these mutations are chain termination mutations.
Codon 53 contains four independent mutations, and three of these are also chain termination mutations . Clearly, missense mutations are selected for between codons 120 and 290, while nonsense mutations are much more common outside of this region. The chain termination codons more likely result in a loss of function mutation. While it is clearly true that most of the experiments that provide nucleotide sequences of mutant p53 cDNAs have focused only on the region between codons 120 and 290 (and so there may well be a bias to find mutations in this region), the qualitative differences between the nature of the mutations occurring inside or outside of the central portion of the gene suggests that there is a selection for missense mutations in one of the protein domains of the p53 gene. It is this conclusion which is at odds with an expected simple 'loss of function' mutation or a simple classification as a tumoursuppressor gene.
Indeed, missense mutant p53 proteins do exhibit several phenotypes or activities that suggest they actively contribute in some fashion to abnormal cell growth. Missense mutant THE p53 TUMOUR-SUPPRESSOR GENE 411 p53 genes can cooperate with an activated ras oncogene and transform primary rat embryo fibroblasts in cell culture (Eliyahu et al., 1984; Parada et al., 1984) . Similarly, missense p53 mutant alleles enhance the colony-forming ability or plating efficiency of primary rat cells in culture (Finlay et al., 1989) . In these cases, it is thought that the faulty p53 protein forms a tetrameric protein complex with the endogenous wild-type p53 protein in the cell, and such mutant-wild type complexes, which have been demonstrated to exist (Finlay et al., 1988; Martinez et al., 1991) . Since these cells contain no endogenous wild-type p53 proteins to be inactivated by the p53 mutant protein, these data indicate that the altered p53 protein itself can contribute a new function to these cells .
These observations indicate that the p53 missense mutants have lost some functions, as expected for a tumoursuppressor gene, but have also gained new activities and therefore this gene is more like an hermaphrodite in the scheme of oncogenes and tumour-suppressor genes. This may account for the fact that mutations at the p53 locus are the single most common genetic alteration now observed in human cancers. The p53 gene is found in a mutant form in about 70% of colorectal cancers, 50% of lung cancers and 30-40% of breast cancers .
A role for tissue-specific mutagens in the environment While these observations and arguments strongly implicate the role of selection for specific mutations in shaping the spectrum or distribution of mutations observed in the p53 gene, other forces appear to play an important part in this process. Figure 3 shows the distribution of p53 mutations in specific cancers of the colon, lung, breast and liver. These distributions of p53 mutations share some similarities, but some mutant alleles are preferred or are unique to the cell or tissue type of the cancer. Such differences might arise from either tissue-specific selection of a particular mutant allele or from the exposure of different tissues to different environmental mutagens, which could act to produce a distinct type of mutation in these tissues. If this latter hypothesis were correct, the different mutations specific to a tissue type would result from the nature of the mutagen exposure and its specific mode of action. The mutational profiles in Figure 3 would be a kind of 'Ames test' carried out in the human population at the p53 locus. There is some evidence in favour of this idea. Figure 4 contrasts the frequency of transition mutations and transversion mutations observed in the p53 gene from cancers of different tissues. Since distinct mutagens initiate these different types of mutations, the significant differences in the ratio of transition to transversion mutations Codon number Figure 3 The distribution of p53 mutations in human tumours from colon, lung, breast and liver.
in each tissue is most consistent with the idea that different mutagens act upon different tissues of the body. For example, lung cancers show more transversion mutations than colon or stomach cancers. This may be expected from the mutagens in cigarette smoke, such as benzpyrene, which preferentially produce transversion mutations. Codon 157 mutations are found almost exclusively in lung tumours ( Figure 3 ) and are always transversion mutations. In a similar fashion, all of the basal cell carcinomas and most of the squamous cell carcinomas of the skin result from the mutations caused by ultraviolet light (pyrimidine photoproducts) and are solely transition mutations. Finally, the common mutation at codon 249 of hepatocellular carcinomas derived from specific geographic locations, such as southern China and the southern parts of Africa (Bressac et al., 1991; Hsu et al., 1991) , most probably arise from the presence of the fungus that produces aflatoxin B1 in peanut crops of those areas. In regions where peanut crops are inspected and aflatoxin Bl eliminated, the mutation at this codon occurs at a much lower frequency.
Thus, it appears likely that the unusual distribution of p53 mutations seen in Figures 2 and 3 derives from a combination of the diverse mutagens inducing these events, which appear to differ for different tissues, and by selection for a mutant missense allele with a particular altered phenotype that may contribute to abnormal cell cycle events.
The p53 tumour-suppressor gene and its protein
The p53 gene is located in 16-20 kb of DNA on the short arm of human chromosome 17, at position l7pl3.1 (Ben- (Seto et al., 1992 (Fields & Jang 1990; Raycroft et al., 1990) . Thus, the amino-terminal 75 amino acid residues can act to promote transcription if brought to the DNA by a DNA-binding domain. The region of the p53 protein between residues 120 and 290 can act as a specific DNAbinding domain, interacting with a p53 recognition element. The consensus nucleotide sequence for p53 binding to DNA is 5'-Pu-Pu-Pu-C-A/T-A/T-G-Py-Py-Py-3' (El-Diery et Funk et al., 1992 (Stenger et al., 1992) . Thus, the p53 protein is a transcription factor that enhances the rate of transcription of a gene that has a p53 responsive element, and this has been shown both in vivo and in vitro (Farmer et al., 1992) . The missense mutations found in the p53 gene from cancerous cells produce a faulty protein that no longer binds as efficiently to this specific DNA sequence (mutations are clustered in the DNA-binding domain) (Bargonetti et al., 1991) and no longer promotes the transcription of a gene with the p53 responsive element . This is the phenotype of one of the loss of function mutations at the p53 locus.
For many genes that do not contain a p53 responsive element in their regulatory regions, the p53 protein inhibits or negatively regulates transcription (Malkin et al., 1990; Srivastava et al., 1990) . This definition has been recently extended to include larger family groupings with multiple neoplasms in whom sarcomas (especially osteogenic sarcoma) are detected early in life (Levine, 1992b; Toguchida et al., 1992) . The cancers that arise in these families contain the mutant allele and commonly a reduction to homozygosity at this locus so that no wild-type alleles are present in the cancer. Transgenic mice that inherit one mutant p53 allele also have a higher than normal frequency of cancer in their offspring (Lavigueur et al., 1989) . Mice with no p53 wild-type alleles all develop cancer in 6-9 months (Donehower et al., 1992) . (Hollstein et al., 1991; Levine et al., 1991) , while other cancers never seem to accumulate p53 mutations (neuroblastoma, testicular teratocarcinoma, acute lymphatic leukaemia) (Jonveaux & Berger, 1991; Heimdel et al., 1993) . A number of recent studies have indicated that the presence of a p53 mutation in a particular cancer indicates a poor prognosis for response to chemotherapeutic treatment and survival (Callahan, 1992) . The rationale for this correlation is becoming clear as the functions of the p53 protein are explored, and these concepts will be detailed in the next section.
Returning the wild-type p53 gene into cancer cells (Mercer et al., 1990) or cells being transformed by oncogenes (Finlay et al., 1989) blocks transformation and reduces the tumorigenic potential of these cells. Cells transformed by a temperature-sensitive mutant of the p53 gene replicate rapidly at 39°C, but fail to duplicate at 32°C (Martinez et al., 1991; Michalowitz et al., 1991) . In these cells, the p53 protein is preferentially in the mutant form at 39°C and the wild-type form at 32°C (Martinez et al., 1991; Michalowitz et al., 1991) . The wild-type protein blocks these cells from progressing past GI (Martinez et al., 1991) Levine, 1979) in transformed cells and inactivates the functions of these putative checkpoint controls. p53 in a T antigen-p53 complex can no longer bind to a p53 responsive DNA element and fails to act as a transcription factor (Mietz, et al., 1992) . Similarly, the adenovirus E1B 55 kDa protein (an oncogene product) binds to p53 protein (Sarnow et al., 1982) and blocks its ability to act as a transcription factor (Yew & Berk, 1992) . In this case the EIA oncogene product of adenovirus binds to Rb (Whyte et al., 1988) . The human papillomaviruses encode two oncogenes, termed E6 and E7 (Munger et al., 1992) . The E6 protein binds to p53 ) and the E7 protein to Rb (Dyson et al., 1989 ) (see Table II ). The E6-p53 complex is targeted for proteolytic degradation, utilising the ubiquitin system, resulting in a loss of p53 protein and therefore a loss of p53 function in these cells (Scheffner et al., 1990) . Thus, three quite diverse virus groups, each capable of initiating tumours in humans (papillomaviruses) or animals, have targeted the major tumour-suppressor gene products of the cell, Rb and p53. Importantly, these virus-encoded oncogene products inactivate p53-mediated transcription much like the mutations observed in the p53 gene from human cancers.
Recently, a cellular protein encoded by an oncogene, termed mdm-2 (Fakharzadeh et al., 1991) , has also been shown to bind to the p53 protein and inactivate its ability to function as a transcription factor . When the mdn-2 gene is amplified in mouse cells (Fakharzadeh et al., 1991) , the elevated levels of mdm-2 proteins enhance the tumorigenic potential of these cells. Whether mdm-2 proteins act by inactivating the wild-type p53 protein or have an intrinsic activity of their own remains to be determined. In either case, a number of human sarcomasliposarcoma, osteogenic sarcoma or fibrous histiocytic sarcomas -contain amplified copies of the mdn-2 gene (Oliner et al., 1992) . Some of these tumours have both mdn-2 amplifications and p53 mutations (about 10%), and this group has a poorer prognosis for long-term survival than sarcoma patients with no p53 or mdn-2 mutations or patients with p53 or mdn-2 mutations alone (Cordon-Cardo et al., 1993) . Clearly, gene functions that regulate the p53 gene or gene product will act as either oncogenes (negative regulation) or tumour-suppressor genes (positive regulation) and these regulatory proteins will be central to our understanding of cancer in humans.
The functions of the p53 gene product
The levels of p53 protein in a cell are dramatically increased (5 to 60-fold) in response to exposure to DNA-damaging agents such as UV or gamma-irradiation or chemicals that react with DNA (Maltzman & Czyzyk, 1984; Kastan et al., 1991) . After gamma-irradiation, double-stranded breaks in the DNA must be repaired prior to DNA replication, chromosome packaging and segregation. If the damaged DNA participates in replication or chromosome segregation, then mutations occur at a high frequency and chromosome segregation may be faulty. This results in a high rate of cell death and rare mutant clones of cells that grow in an uncontrolled fashion. After gamma-irradiation, the high p53 levels block progression of the cell cycle in the GI phase, so as to permit DNA repair prior to proceeding with DNA replication (Kuerbitz et al., 1992) . The increased levels of p53 result from an enhanced stability of the p53 protein. In response to DNA damage, the half-life of the p53 protein increases from 20-30 min in normal cells to hours in cells that were recently irradiated (Maltzman & Czyzyk, 1984; Kastan et al., 1991) . Thus, the p53 protein acts as a checkpoint control in the cell cycle, blocking progression of cells in GI and preventing entry into S-phase, in response to an environmental insult. This does not permit the duplication of damaged DNA and minimises errors in the cell cycle. p53 enhances the fidelity of the cell cycle by monitoring cells for damaged DNA.
One of the mutations that results from DNA exposed to gamma-irradiation is gene amplification. The single-and double-strand ends of broken DNA are aggressive recombination intermediates, and unequal crossing over or gene conversion duplicates genetic loci, which are subsequently amplified into many copies of DNA. Such mutations are of course the hallmark of several oncogene mutations (Brugge et al., 1991) . Cells with no p53 proteins (null mutations) will amplify their DNA at least one million times more readily than observed in cells containing wild-type p53 protein (Livingstone et al., 1992; Yin et al., 1992) . Thus, a growing body of evidence indicates that the p53 protein monitors the integrity of the genome and minimises the mutations which arise from exposure to DNA-damaging agents.
The p53 protein might accomplish this in one of several ways. The enhanced levels of p53 protein should regulate the transcription of a set of genes with p53 responsive elements. To date, two such genes have been identified.
(1) GADD-45 is a gene whose level of transcription is increased in response to DNA damage and whose levels are highest in resting or non-cycling cells (Fornace et al., 1989) . The gene for GADD-45 contains a p53 responsive element in the third intron, and p53 protein isolated from irradiated cells binds to this DNA element .
(2) The mdn-2 gene, contains a p53 responsive element in the first intron of this gene, and p53 protein has been shown to bind specifically to this DNA sequence . mdm-2 is an oncogene whose product might be expected to promote entry of cells into cycle or S-phase. Thus, p53 may utilise the regulation of GADD-45 to block progression through the cell cycle in GI and mdm-2 to reverse this process and commit cells to S-phase after the DNA repair process. At high doses of ultraviolet light, cells induce p53 to high levels and the induction of mdm-2 mRNA and protein is delayed, occurring about the same time cells enter S-phase (Perry et al., 1993) . Thus, p53 could control the transcription of a set of genes to block cells in GI and then overcome this block to permit re-entry into the cycle. In this case, additional factors would control when p53 stimulates transcription of GADD-45 and mdm-2 genes (Perry et al., 1993 ) (see Figure 5 ). Figure 5 The level and specificity of p53 transcriptional transactivation activity in response to DNA damage may be regulated by other transcription factors.
In some cell types, enhanced levels of p53 protein appear to direct the cells into a pathway for programmed cell death or apoptosis (Yonish-Rouach et al., 1991; Shaw et al., 1992) . In thymic T cells derived from mice with wild-type p53 protein, exposure to ionising radiation induces apoptosis. In thymic T cells derived from mice with no p53 protein (null mutations), exposure to irradiation fails to lead to programmed cell death (Clarke et al., 1993; Lowe et al., 1993) . Thus, the DNA damage utilises the p53 protein pathway to commit to apoptosis. For cells damaged so badly that efficient repair is not feasible, a pathway to cell death is preferable to sustain the life of the organism. Mutations in the p53 gene would then permit abnormal cell clones to arise after DNA damage. It is relevant that the most common tumour type observed in mice homozygous for the p53 null alleles is a T-cell lymphoma (Donehower et al., 1992) .
Cancers containing a wild-type p53 allele have a better prognosis for responses to chemotherapy and survival than cancers with p53 mutations (Callahan, 1992) . It is of considerable interest then that these interpretations of the functions of the p53 protein predict how radiation or cancer chemotherapy acts to preferentially kill cancerous cells and not normal cells. Most chemotherapeutic agents and radiation treatments damage DNA. In normal cells or cancer cells with wild-type p53 proteins, this induces high p53 levels, which then may block cells in GI to permit DNA repair or, if the damage is very extensive, kill the cells via apoptosis. Cancer cells with p53 mutations enter S-phase and duplicate damaged DNA. They segregate their chromosomes abnormally, and these processes result in a good deal of cell death. These cells also fail to enter into the pathway for apoptosis even with extensively altered DNA. The result is the progressive appearance of more abnormal cells and clones of cells that evolve into more aggressive cancers.
If these ideas are correct, it will become important to determine the status of the p53 gene and the mdn-2 gene in cancer cells so as to determine the best treatment protocols (Lowe et al., 1993) . Similarly, individuals with germline p53 mutations (Levine, 1992b) who develop cancers may well need to be treated differently from those whose normal cells are homozygous for both p53 wild-type alleles.
The available evidence favours a role for the p53 protein as a checkpoint in cell cycle progression, permitting repair of DNA damage and prevention of gene amplifications. In some cell types, high levels of p53 protein act as a switch to turn on a pathway to apoptosis in a cell responding to DNA alterations (see Figure 6 ). It appears likely that p53 can mediate these activities, probably by its functioning as a transcription factor. To date we know of only two clear examples of genes regulated by p53 transcriptional transactivation activity Wu et al., 1993) , GADD45 and mdn-2. There are probably other genes regulated by high p53 protein levels, and the search for them will be an important avenue for future efforts. In addition, the modulation of p53 transcriptional activation by other gene products will need to be understood (see Figure 5 ) and explored in future experimentation. For example, the expression of the mdm-2 gene is autoregulated because it has a p53 responsive element and, when more mdm-2 protein is synthesised, it binds to p53 protein and reduces p53-mediated transcriptional activation Wu et al., 1993) . There are probably additional positive and negative regulators of p53 synthesis and/or activity. It remains possible that the p53 protein plays a direct role (not only via transcription of other genes) in the process of monitoring DNA damage or recombination intermediates in a cell. The p53 protein itself binds with high affinity to single-strand DNA and RNA and catalyses the annealing of these nucleic acids into double-stranded DNA or RNA (Oberosler et al., 1993) . It would be expected that the p53 protein should antagonise critical helicase activities utilised in DNA replication and recombination. This could block aggressive singlestrand recombination intermediates that lead to gene duplications, amplifications and oncogene activations. Thus, it remains possible that the p53 protein monitors the integrity of the host genome by acting directly upon DNA as well as via the regulation of other gene products. Elucidating the functions of the p53 protein will go a long way to understanding the origins of human cancers.
